(Bloomberg) -- Sanofi-Aventis SA's weight-loss pill
Acomplia isn't yet approved in the U.S. after months of delay
and questions about its safety. Some Americans aren't waiting.
People are traveling to Europe or buying the medicine
through foreign Web sites after the U.S. Food and Drug
Administration postponed a decision three times in 16 months. A
panel of advisers to the agency will meet this week to review
the drug, the first of its type that blocks hunger receptors in
the brain. Sanofi has predicted at least $3 billion in annual
revenue, about 8.6 percent of last year's pharmaceutical sales.
Read more at Bloomberg Exclusive News
Acomplia isn't yet approved in the U.S. after months of delay
and questions about its safety. Some Americans aren't waiting.
People are traveling to Europe or buying the medicine
through foreign Web sites after the U.S. Food and Drug
Administration postponed a decision three times in 16 months. A
panel of advisers to the agency will meet this week to review
the drug, the first of its type that blocks hunger receptors in
the brain. Sanofi has predicted at least $3 billion in annual
revenue, about 8.6 percent of last year's pharmaceutical sales.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment